B

ristol-Myers Squibb reported positive results Monday in a crucial immunotherapy trial, using a combination of the two drugs Opdivo and Yervoy to treat patients with a specific type of non-small cell lung cancer patients.

But previously undisclosed changes made by Bristol to the study, known as Checkmate-227, are raising questions about the validity and strength of the results.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

  • This isn’t quite true. TMB was added as co-primary endpoint before the study enrollment stopped. PDL is still in trials which is continuing. TMB data on progression free survival showed enough impact it hit endpoint early so the data was released

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.